CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 170 filers reported holding CLOVIS ONCOLOGY INC in Q3 2016. The put-call ratio across all filers is 0.79 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $101,000 | -24.6% | 49,947 | +1.4% | 0.00% | – |
Q4 2021 | $134,000 | -41.0% | 49,243 | -3.1% | 0.00% | – |
Q3 2021 | $227,000 | -2.2% | 50,815 | +26.8% | 0.00% | – |
Q2 2021 | $232,000 | +58.9% | 40,072 | +92.5% | 0.00% | – |
Q1 2021 | $146,000 | +82.5% | 20,818 | +24.6% | 0.00% | – |
Q4 2020 | $80,000 | -93.5% | 16,704 | -85.8% | 0.00% | – |
Q4 2019 | $1,228,000 | +1981.4% | 117,780 | +690.4% | 0.00% | – |
Q3 2019 | $59,000 | -74.3% | 14,902 | -3.6% | 0.00% | – |
Q2 2019 | $230,000 | -42.1% | 15,460 | -3.3% | 0.00% | – |
Q1 2019 | $397,000 | -95.9% | 15,991 | -95.1% | 0.00% | -100.0% |
Q3 2018 | $9,578,000 | -38.6% | 326,122 | -4.9% | 0.00% | -40.0% |
Q2 2018 | $15,600,000 | -14.9% | 343,101 | -1.1% | 0.01% | -28.6% |
Q1 2018 | $18,326,000 | -23.9% | 347,086 | -2.0% | 0.01% | -22.2% |
Q4 2017 | $24,075,000 | -39.2% | 354,045 | -26.3% | 0.01% | -40.0% |
Q3 2017 | $39,599,000 | +2.9% | 480,582 | +16.9% | 0.02% | +25.0% |
Q2 2017 | $38,484,000 | +41.4% | 411,024 | -3.9% | 0.01% | +33.3% |
Q1 2017 | $27,222,000 | +436.2% | 427,564 | +274.1% | 0.01% | +350.0% |
Q4 2016 | $5,077,000 | +1169.2% | 114,298 | +929.2% | 0.00% | – |
Q3 2016 | $400,000 | -86.8% | 11,105 | -87.1% | 0.00% | -100.0% |
Q4 2015 | $3,024,000 | -82.5% | 86,399 | -53.9% | 0.00% | -85.7% |
Q3 2015 | $17,236,000 | +37.9% | 187,422 | +31.7% | 0.01% | +40.0% |
Q2 2015 | $12,502,000 | +57.8% | 142,258 | +33.3% | 0.01% | +66.7% |
Q1 2015 | $7,922,000 | -16.1% | 106,720 | -36.7% | 0.00% | -25.0% |
Q4 2014 | $9,443,000 | +36.3% | 168,631 | +10.4% | 0.00% | +33.3% |
Q3 2014 | $6,929,000 | +17.2% | 152,753 | +7.0% | 0.00% | +50.0% |
Q2 2014 | $5,913,000 | -45.5% | 142,789 | -8.9% | 0.00% | -50.0% |
Q1 2014 | $10,859,000 | +335.9% | 156,760 | +279.3% | 0.00% | +300.0% |
Q4 2013 | $2,491,000 | +271.2% | 41,330 | +312.4% | 0.00% | – |
Q2 2013 | $671,000 | – | 10,021 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |